CTIS2024-512495-35-00招募中1 期
Adjuvant treatment with Pramipexole for anhedonia symptoms in depression - PRIME-PRAXO
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Region Skane
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age =18 years =75 years., Diagnosis of unipolar depressive episode, bipolar disorder in depressive phase, or dysthymia., Anhedonia symptoms: 3 or 4 points on = 3 items of the Snaith-Hamilton Pleasure Scale (SHAPS-C)., Ongoing treatment with at least one antidepressant or mood stabilizing medication = 4 weeks., Has tried an antidepressant at a therapeutic dose but not achieved remission (refractory stage 1 depression)., The research subject has given informed consent to participate in the study.
排除标准
- •Pregnancy, breastfeeding or planned pregnancy (if female)., Recently started psychotherapy (within 6 weeks) or planning to start such treatment during participation in the trial., Ongoing or planned ECT, ketamine or rTMS treatment, excluding maintenance ECT, ketamine or rTMS (Maintenance treatment is defined as the use of ECT/ketamine/rTMS for a period exceeding 3 months after a series of ECT/ketamine/rTMS treatment in order to prevent the onset of a new episode)., Other medical conditions or other concomitant drug treatment which, in the opinion of the investigators, may affect the evaluability of the trial or conditions that increase trial risk. For example, Parkinson's disease, hepatic insufficiency, ongoing cancer not in remission for more than one year, bariatric surgery with a known impact on absorption of extended-release tablets., Known or suspected allergy to any active substance or excipient in the medicinal product included in the trial., Participation in other treatment studies., Other reason, as assessed by the investigator, that prevents the research subject's participation, such as the risk that the research subject is unable to complete the trial (non-compliance)., High suicide risk according to the overall clinical assessment of the research physician., Ongoing substance abuse (within 6 months)., Diagnosis of current psychosis., Known diagnosis of Emotionally Unstable Personality Disorder., Treatment under LPT., History of or a strong clinical suspicion of impulse control disorder (including current bingeeating disorder) or a current ADHD diagnosis with hyperactivity., Diagnosis of intellectual disability, dementia, or other circumstance that makes it difficult to understand the meaning of participating in the trial and give informed consent., Diagnosis of renal failure (eGFR < 50 ml/min/1,73 m2) or severe cardiovascular disease (specifically symptomatic heart failure NYHA Class II or higher).
研究者
相似试验
进行中（未招募）
1 期
Pramipexole augmentation to target anhedonia in depression - a pilot studyDepressionEUCTR2019-001907-19-SERegion Skåne15
已完成
不适用
Adjunctive treatment with pramipexole for antipsychotic-induced hyperprolactinemia in patients with schizophrenia, Reserch for efficacy and tolerability.schizophreniaJPRN-UMIN000006556Department of Neuropsychiatry,University of Fukui20
招募中
3 期
Adjuvant treatment with Pramipexole for anhedonia symptoms in depression - PRIME-PRAXOL2024-512495-35-00Region Skane140
进行中（未招募）
1 期
Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD): Pilot, Randomized and Controlled Clinical TrialObsessive-compulsive disorder (OCD)MedDRA version: 20.0Level: LLTClassification code: 10030029Term: OCD Class: 10037175CTIS2024-511085-37-00CCAB Centro Clinico Academico Braga Associacao48
招募中
2 期
Efficacy of pramipexole treatment and methylphenidate for attention deficit hyperactivity disorderattention deficit hyperactivity disorder.Disturbance of activity and attentionIRCT20100520003979N7Ahvaz University of Medical Sciences10